P-272 The international, open-label, multicenter phase 2 LAPACT trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) for patients with locally advanced pancreatic cancer (LAPC)

Autor:	García-Paredes Beatriz, Shiansong Li Jack, Nydam Thomas, Terrebonne Eric, Bathini Venu, Hammel Pascal, Asselah Jamil, Kim Edward, Philip A. Philip, Portales Fabienne, Rivera Fernando, Manzano Jose Luis, Dowden Scot, Lacy Jill, Sobrero Alberto, Kayitalire Louis
Rok vydání:	2016
Předmět:	Oncology medicine.medical_specialty business.industry Hematology medicine.disease Gemcitabine Locally advanced pancreatic cancer Abstracts Text mining Paclitaxel protein-bound Internal medicine Pancreatic cancer medicine Open label business medicine.drug Nab-paclitaxel
Zdroj:	Annals of Oncology. 27:ii78
ISSN:	0923-7534
DOI:	10.1093/annonc/mdw199.262
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fff39c06690a50e387181c45b81d4780 https://doi.org/10.1093/annonc/mdw199.262 Zobrazit plný text záznamu